Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. Among authors: bedossa p. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.
Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S, Le Marchand-Brustel Y, Clement K, Van Gaal L, Sørensen TIA, Jess T. Zimmermann E, et al. Among authors: bedossa p. J Hepatol. 2011 Sep;55(3):660-665. doi: 10.1016/j.jhep.2010.12.017. Epub 2011 Jan 14. J Hepatol. 2011. PMID: 21238518
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte F, Bedossa P, Mathurin P, Ratziu V; FLIP consortium. Poynard T, et al. Among authors: bedossa p. PLoS One. 2012;7(3):e30325. doi: 10.1371/journal.pone.0030325. Epub 2012 Mar 14. PLoS One. 2012. PMID: 22431959 Free PMC article.
N-butyl-2-cyanoacrylate in gastric varices: a cause for recurrent sepsis.
Ausloos F, Hillaire S, Bedossa P, Bert F, Moreno C, Geubel A, Plessier A, Valla D. Ausloos F, et al. Among authors: bedossa p. Am J Gastroenterol. 2013 Dec;108(12):1937-8. doi: 10.1038/ajg.2013.288. Am J Gastroenterol. 2013. PMID: 24300876 No abstract available.
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.
Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Ratziu V, et al. Among authors: bedossa p. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12. Clin Gastroenterol Hepatol. 2014. PMID: 24530600 Clinical Trial.
Diagnosis of liver fibrosis: present and future.
Patel K, Bedossa P, Castera L. Patel K, et al. Among authors: bedossa p. Semin Liver Dis. 2015 May;35(2):166-83. doi: 10.1055/s-0035-1550059. Epub 2015 May 14. Semin Liver Dis. 2015. PMID: 25974902 Review.
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group. Ratziu V, et al. Among authors: bedossa p. Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11. Gastroenterology. 2016. PMID: 26874076 Free article. Clinical Trial.
506 results